Pharmacology of lipid formulations of amphotericin B

Infectious Diseases in Clinical Practice

Volumn 7, Issue SUPPL. 1, 1998, Pages

  Dix, Suzanne P ^a,b  

^a ST LUKE S HOSPITAL   (United States)

^b Oncol Hematol Assoc Kansas City   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; LIPOSOME;

ANTIFUNGAL ACTIVITY; DRUG FORMULATION; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MYCOSIS; NEPHROTOXICITY; NONHUMAN; REVIEW;

EID: 0031919875     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199803000-00003     Document Type: Review

References (71)

1. Saral R. Candida and aspergillosis infections in immunocompromised patients: an overview. J Infect Dis 1991;13: 487-92.
2. Walsh TJ, Pizzo PA Treatment of systemic fungal infections recent progress and current problems Eur J Clin Microbiol Infect Dis 1988;7:460-75.
3. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22 (20 Suppl): 133S-144S.
4. Walsh TJ. Management of immunocompromised patients with evidence of an invasive mycosis. Hematol Oncol Clin North Am 1993;7:1003-26.
5. Sarosi GA Amphotericin B: still the "gold standard" for antifungal therapy. Postgrad Med 1990;88:151-66.
6. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
7. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce toxicity of amphotericin B. Proc Natl Acad Sci USA 1988;85:6122-6.
8. Janoff AS, Perkins WR, Saleton SL, et al. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B-related toxicities J Liposome Res 1993;3:451-72
9. Lopez-Berestein G, Hopfer RL, Mehta R, et al. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice J Infect Dis 1984;150:278-83.
10. Lopez-Berestein G, Fainstein V, Hopfer R, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985;151:704-10.
11. Lopez-Berestein G, Bodey GP, Frankel LS, et al Treatment of hepatosplenic candidiasis with liposomal-amphotericin B J Clin Oncol 1985;151:310-7.
12. Bangham AD. Liposomes: realizing their promise. Hosp Pract 1992;27:51-6.
13. Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 1989;46:1576-87.
14. Gregoariadis G, editor. Liposome technology. Vols 1-3. 1st ed. Boca Raton (FL): CRC Press; 1984.
15. Fielding RM. Liposomal drug delivery: advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clin Pharmacokinet 1991;21:155-64.
16. Lichtenberg D, Barenholz Y. Liposomes: preparation, characterization and preservation. Methods Biochem Anal 1988;33:337-462.
17. Janknegt R, deMarie S, Bakker-Woudenberg IA, et al. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992;23:279-91.
18. Janoff AS. Liposomes and lipid structures as carriers of amphotericin B. Eur J Clin Microbiol Infect Dis 1990;9: 146-51.
19. Guo LSS, Fielding RM, Lasic DD, et al. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int J Pharm 1991;75:45-51.
20. Guo LSS, Fielding RM, Gantz DL, et al. Structure of amphotericin B colloidal dispersion: a novel amphotericin B dosage form [abstract 221]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991 Sep 29-Oct 2; Chicago. Washington (DC): American Society for Microbiology, 1991.
21. deMarie S. Liposomal and lipid-based formulations of amphotericin B Leukemia 1996;10(2 Suppl):93S-96S.
22. Juliano RL, Grant CW, Barber KR, et al. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 1987;31:1-11
23. Sculier JP, Coune A, Meunier F, et al. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 1988;24:527-38.
24. Abelcet product information. The Liposome Company, Princeton (NJ), October 1996.
25. Amphotec product information. SEQUUS Pharmaceuticals, Menlo Park (CA), October 1996.
26. AmBisome product information. NeXstar Pharmaceuticals, Oakleigh, Victoria, Australia, December 1996
27. Moreau P, Milpied N, Fayette N, et al. Reduced renal toxicity and improved clinical tolerance of amphotericin B in neutropenic patients. J Antimicrob Chemother 1992; 30 535-41
28. Chavanet PY, Garry I, Charlier N, et al. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ 1992; 305:921-5.
29. Caillot D, Casasnovas O, Solary E, et al. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993;31:161-9.
30. Kirsh R, Goldstein R, Tarloff J, et al. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 1988;158:1065-70.
31. Trissel LA. Amphotericin B does not mix with fat emulsion [letter]. Am J Health Syst Pharm 1995;52:1463-4.
32. Data on file. The Liposome Company, Princeton (NJ)
33. Data on file. SEQUUS Pharamceuticals, Menlo Park (CA).
34. Adler-Moore JP, Profitt RT. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993;3:429-50.
35. Atkinson AJ, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978;13: 271-6.
36. Daneshmend TK, Warnock DW. Clinical pharamcokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983;8:17-42.
37. Christiansen KJ, Bernard EM, Gold JW, et al. Distribution and activity of amphotericin B in humans. J Infect Dis 1985;152:1037-43.
38. Amantea MA, Bowden RA, Forrest A, et al Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother 1995;39:2042-7.
39. Benson JM, Nahata MC. Clinical use of systemic antifungal agents. Clin Pharm 1988;7:424-38.
40. Morgan DJ, Ching MS, Raymond K, et al. Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther 1983;34:248-53.
41. Clark JM, Whitney RR, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice Antimicrob Agents Chemother 1991;35:615-21.
42. Lee J, Allende M, Amantea M, et al. Pharmacokinetics and efficacy of amphotericin B lipid complex (ABLC) against chronic disseminated candidiasis in rabbits [abstract 579]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991 Sep 29-Oct 2; Chicago. Washington (DC): American Society for Microbiology; 1991.
43. Olsen SJ, Swerdel MR, Blue B, et al. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 1991;43:831-5.
44. Fielding RM, Smith PC, Wang LH, et al. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 1991;35:1208-13.
45. Fielding RM, Singer AW, Wang LH, et al. Relationship of pharmacokinetics and drug disposition in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 1992;36:299-307.
46. Sanders SW, Buchi KN, Goodard MS, et al. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 1991;35: 1029-34.
47. Gondal JA, Swartz RP, Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 1989;33:1544-8.
48. Profitt RT, Satorius A, Chiang SM, et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991; 28(B Suppl):49-61.
49. Heinemann V, Kahny B, Debus A, et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant 1994;14(1 Suppl):8S-9S.
50. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28 (B Suppl):73-82.
51. Anaissie E, Paetznick B, Profitt R, et al. Comparison of the in vitro antifungal activity of free and liposomal-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1991;10:665-8.
52. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.
53. Lister J. Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996;56(57 Suppl):18-23.
54. Wolff MA, Ramphal R. Use of amphotericin B lipid complex for treatment of disseminated cutaneous fusarium infection in a neutropenic patient [letter]. Clin Infect Dis 1995;20:1568-9
55. Patterson TS, Barton LL, Shehab ZM, et al Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection Clin Pediatr 1996; May:257-60.
56. Pahls S, Schaffner A. Comparison of the activity of free and lipsomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J Infect Dis 1994;169:1057-61.
57. Clemons KV, Stevens DA. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother 1991;35:2144-6.
58. Allendorfer R, Yates RR, Sun SH, et al. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. J Med Vet Mycol 1992;30:377-84.
59. Lee J, Allende M, Dollenberg H, et al. Reticuloendothelial loading with amphotericin B lipid complex (ABLC): a novel pharmacodynamic approach to treatment of experimental hepatosplenic candidiasis (HSC) [abstract 172]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy: 1992 Oct 11-14. Anaheim (CA). Washington (DC): American Society for Microbiology; 1992
60. Joly V, Bolard J, Saint-Julien L, et al. Influence of phospholipid/amphotericin B ration and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid associated amphotericin B formulation. Antimicrob Agents Chemother 1992;36:262-6.
61. Fielding RM, Porter J, Jekot J, et al. Altered tissue distribution results in the reduced toxicity of amphotericin B colloidal dispersion [abstract A77]. In: Proceedings of the 91st Annual Meeting of the American Society for Microbiology; Dallas (TX). Washington (DC): American Society for Microbiology; 1991. p. 13.
62. Lee JW, Amantea MA, Francis PA, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994;38:1544-8.
63. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob Chemother 1991;28(B Suppl): 83-91.
64. Hiemenz JW, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B. Blood 1995;86:3383a.
65. Sharkey PK, Graybill JR, Johnson ES, et al Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21.
66. Sharkey PK, Lipke R, Renteris A, et al. Amphotericin B lipid complex (ABLC) in treatment of coccidioidomycosis [abstract 742]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991 Sep 29-Oct 2; Chicago. Washington (DC): American Society for Microbiology; 1991.
67. Hostetler JS, Caldwell JW, Johnson RH, et al. Coccidioidal infections treated with amphotericin B colloidal dispersion (Amphocil or ABCD) [abstract 628]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11-14; Anaheim (CA.). Washington (DC): American Society for Microbiology, 1992. p. 215.
68. Bowden RA, Cays M, Gooley T, et al. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15.
69. White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997;24:635-42.
70. Prentice HG, Catovsky D, Aoun M, et al. AmBisome versus amphotericin B in patients with fever unresponsive to antibiotic therapy for 96 hours, or with confirmed fungal infection [absract 35] In: Scientific program and abstracts of the 2nd International Symposium on Febrile Neutropenia; 1995 Dec 14-16; Brussels (Belgium).
71. Hann IM, Stevens RF, Pinkerton CR, et al. Safety and efficacy of two doses of AmBisome versus amphotericin B as empiric antifungal treatment in neutropenic paediatric patients [abstract 25]. In: Scientific program and abstracts of the 2nd International Symposium on Febrile Neutropenia; 1995 Dec 14-16; Brussels (Belgium).